Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, Decock J, Wildiers H, Paridaens R, Amant F, Leunen K, Berteloot P, Timmerman D, Van Limbergen E, Weltens C, Van den Bogaert W, Smeets A, Vergote I, Christiaens MR, Drijkoningen M. Neven P, et al. Among authors: van calster b, van huffel s, van belle v, van den bempt i, van den bogaert w, van limbergen e. Breast Cancer Res Treat. 2008 Jul;110(1):153-9. doi: 10.1007/s10549-007-9687-4. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687649
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, Hendrickx W, Decock J, Huang HJ, Leunen K, Amant F, Berteloot P, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Timmerman D, Van Gorp T, Smeets A, Van den Bogaert W, Vergote I, Christiaens MR, Neven P. Van Calster B, et al. Among authors: van huffel s, van gorp t, van den bogaert w, van limbergen e. Breast Cancer Res Treat. 2009 Jan;113(1):181-7. doi: 10.1007/s10549-008-9914-7. Epub 2008 Feb 9. Breast Cancer Res Treat. 2009. PMID: 18264760
Lifestyle changes and breast cancer prognosis: a review.
Kellen E, Vansant G, Christiaens MR, Neven P, Van Limbergen E. Kellen E, et al. Among authors: van limbergen e. Breast Cancer Res Treat. 2009 Mar;114(1):13-22. doi: 10.1007/s10549-008-9990-8. Epub 2008 Apr 4. Breast Cancer Res Treat. 2009. PMID: 18389367 Review.
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P. Brouckaert O, et al. Among authors: van huffel s, van belle v, van den bogaert w, van limbergen e. Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16. Breast Cancer Res Treat. 2009. PMID: 18629635 Clinical Trial.
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
Van Mieghem T, Leunen K, Pochet N, De Moor B, De Smet F, Amant F, Berteloot P, Timmerman D, Vanden Bempt I, Drijkoningen R, Wildiers H, Paridaens R, Smeets A, Hendrickx W, Van Limbergen E, Christiaens MR, Vergote I, Neven P. Van Mieghem T, et al. Among authors: van limbergen e. Breast Cancer Res Treat. 2007 Nov;106(1):127-33. doi: 10.1007/s10549-006-9474-7. Epub 2007 Jan 9. Breast Cancer Res Treat. 2007. PMID: 17211534
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, Billen J, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Weltens C, Van Limbergen E, Van den Bogaert W, Vergote I, Van Huffel S, Christiaens MR, Neven P. Dieudonné AS, et al. Among authors: van huffel s, van den bogaert w, van limbergen e. Breast Cancer Res Treat. 2009 Dec;118(3):531-8. doi: 10.1007/s10549-009-0463-5. Epub 2009 Jul 12. Breast Cancer Res Treat. 2009. PMID: 19597703
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P. Lintermans A, et al. Among authors: van asten k, van limbergen e. Breast Cancer Res Treat. 2014 Jul;146(1):109-16. doi: 10.1007/s10549-014-2986-7. Epub 2014 May 11. Breast Cancer Res Treat. 2014. PMID: 24816806
Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
Brouckaert O, Van Asten K, Laenen A, Soubry A, Smeets A, Nevelstreen I, Vergote I, Wildiers H, Paridaens R, Van Limbergen E, Weltens C, Moerman P, Floris G, Neven P; Multidisciplinary breast centre Leuven. Brouckaert O, et al. Among authors: van asten k, van limbergen e. Breast Cancer Res Treat. 2018 Feb;168(1):189-196. doi: 10.1007/s10549-017-4579-8. Epub 2017 Nov 20. Breast Cancer Res Treat. 2018. PMID: 29159760
213 results